Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Contezolid (Primary) ; Linezolid
- Indications Abscess; Bacterial skin diseases; Cellulitis; Erysipelas; Skin and soft tissue infections; Wound infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors MicuRx Pharmaceuticals
- 07 Oct 2016 Status changed from active, no longer recruiting to completed, as reported by a MicuRx Pharmaceuticals.
- 03 Nov 2015 Top-line results published in a MicuRx media release.
- 31 Aug 2015 According to a MicuRx Pharmaceuticals media release, results from this trial are expected to be available in the fourth quarter of 2015.